768 related articles for article (PubMed ID: 25479935)
1. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
2. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
3. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
St Peter WL; Wazny LD; Weinhandl ED
Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
St Peter WL; Fan Q; Weinhandl E; Liu J
Clin J Am Soc Nephrol; 2009 Dec; 4(12):1954-61. PubMed ID: 19833904
[TBL] [Abstract][Full Text] [Related]
5. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
6. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
Park H; Rascati KL; Keith MS
J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
8. [Hyperphosphatemia in dialysis: which binder?].
Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
[TBL] [Abstract][Full Text] [Related]
11. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
[TBL] [Abstract][Full Text] [Related]
12. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
[TBL] [Abstract][Full Text] [Related]
13. Estimating hospital inpatient cost-savings with sucroferric oxyhydroxide in patients on chronic hemodialysis in five European countries: a cost analysis.
Herrero JA; Salomone M; Ramirez de Arellano A; Schaufler T; Walpen S
J Med Econ; 2021; 24(1):1240-1247. PubMed ID: 34761724
[TBL] [Abstract][Full Text] [Related]
14. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
17. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.
Chiu YW; Teitelbaum I; Misra M; de Leon EM; Adzize T; Mehrotra R
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1089-96. PubMed ID: 19423571
[TBL] [Abstract][Full Text] [Related]
18. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
Yin J; Yin J; Lian R; Li P; Zheng J
BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review.
Rizk R; Hiligsmann M; Karavetian M; Evers SM
Nephrology (Carlton); 2016 Mar; 21(3):178-87. PubMed ID: 26246269
[TBL] [Abstract][Full Text] [Related]
20. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
